tetano
Editor, Senior Moderator
Rev Med Virol
. 2023 Jul 23;e2473.
doi: 10.1002/rmv.2473. Online ahead of print. Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID-19: An updated meta-analysis and trial sequential analysis
Haokun Tian[SUP] 1 2 3 [/SUP], Changsen Yang[SUP] 1 2 3 [/SUP], Tiangang Song[SUP] 1 2 3 [/SUP], Kechen Zhou[SUP] 1 2 3 [/SUP], Lequan Wen[SUP] 1 2 3 [/SUP], Ye Tian[SUP] 1 2 3 [/SUP], Lirui Tang[SUP] 1 2 3 [/SUP], Weikai Xu[SUP] 1 2 3 [/SUP], Xinyuan Zhang[SUP] 1 2 3 [/SUP]
Affiliations
Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019 (COVID-19) patients treated with Paxlovid. According to inclusion and exclusion criteria, databases were used to retrieve articles from 1 January 2020 to 1 January 2023. Article screening, quality evaluation and data extraction were completed and cross-checked. The meta-analysis and trial sequential analysis (TSA) were conducted using RevMan, StataMP, and TSA software. A total of 42 original articles were included. Overall meta-analysis results showed that for death, hospitalisation, death or hospitalisation, emergency department (ED) visit, intensive care unit (ICU) admission, and extra oxygen requirement outcomes, every odds ratio (OR) was <1 and p < 0.05. For rebound outcome, the OR was >1 and p > 0.05. For adverse events (AEs) outcome, the OR was >1 and p < 0.05. In conclusion, Paxlovid effectively reduced the risks of death, hospitalisation, death or hospitalisation, ED visit, ICU admission, and extra oxygen requirement. There was no significant statistical difference considering rebound, but people should pay attention to possible AEs. However, for rebound and AEs outcomes, observations in certain subgroups suggested conclusions contrary to the overall meta-analysis. Trial sequential analysis indicated these two outcomes have a risk of false negative or false positive conclusions, so additional original studies are needed for further validation.
Keywords: COVID-19; efficacy; nirmatrelvir; paxlovid; ritonavir; safety.
. 2023 Jul 23;e2473.
doi: 10.1002/rmv.2473. Online ahead of print. Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID-19: An updated meta-analysis and trial sequential analysis
Haokun Tian[SUP] 1 2 3 [/SUP], Changsen Yang[SUP] 1 2 3 [/SUP], Tiangang Song[SUP] 1 2 3 [/SUP], Kechen Zhou[SUP] 1 2 3 [/SUP], Lequan Wen[SUP] 1 2 3 [/SUP], Ye Tian[SUP] 1 2 3 [/SUP], Lirui Tang[SUP] 1 2 3 [/SUP], Weikai Xu[SUP] 1 2 3 [/SUP], Xinyuan Zhang[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 37485774
- DOI: 10.1002/rmv.2473
Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019 (COVID-19) patients treated with Paxlovid. According to inclusion and exclusion criteria, databases were used to retrieve articles from 1 January 2020 to 1 January 2023. Article screening, quality evaluation and data extraction were completed and cross-checked. The meta-analysis and trial sequential analysis (TSA) were conducted using RevMan, StataMP, and TSA software. A total of 42 original articles were included. Overall meta-analysis results showed that for death, hospitalisation, death or hospitalisation, emergency department (ED) visit, intensive care unit (ICU) admission, and extra oxygen requirement outcomes, every odds ratio (OR) was <1 and p < 0.05. For rebound outcome, the OR was >1 and p > 0.05. For adverse events (AEs) outcome, the OR was >1 and p < 0.05. In conclusion, Paxlovid effectively reduced the risks of death, hospitalisation, death or hospitalisation, ED visit, ICU admission, and extra oxygen requirement. There was no significant statistical difference considering rebound, but people should pay attention to possible AEs. However, for rebound and AEs outcomes, observations in certain subgroups suggested conclusions contrary to the overall meta-analysis. Trial sequential analysis indicated these two outcomes have a risk of false negative or false positive conclusions, so additional original studies are needed for further validation.
Keywords: COVID-19; efficacy; nirmatrelvir; paxlovid; ritonavir; safety.